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Abstract Staphylococcal synergohymenotropic (SHT) toxins 
damage membranes of host defence cells and erythrocytes by the 
synergy of two secreted and non-associated proteins: class S and 
class F components. Whereas Panton-Valentine leucocidin 
(PVL), "/-hemolysin and Luk-M from Staphylococcus aureus are 
members of this toxin family, a new bi-component toxin (LukS- 
I + LukF-I) from Staphylococcus intermedius, a pathogen for 
small animals, was characterised and sequenced. It is encoded as 
a luk-I operon by two cotranscribed genes, like PVL. LukS- 
I + LukF-I shares a strong leukotoxicity of various PMNs, but 
only slight haemolytic properties on rabbit erythrocytes. When 
intradermaHy injected into rabbit skin, a 100 ng dose caused acute 
inflammatory reaction leading to tissue necrosis. The new SlIT 
seemed to be largely distributed among various Staphylococcus 
intermedius trains. 
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1. Introduction 
HlgB). The target cells of these toxins are host defence cells 
such as neutrophils, monocytes and macrophages, and also 
erythrocytes according to the proteins [20]. This family of tox- 
ins was termed synergohymenotropic (SHT) toxins because of 
the synergistical spect of class S and class F components which 
may be intergangeable [20] and because they are membrane 
damaging toxins [6,10]. 
Proteins of class S are known to bind at first to the mem- 
branes of sensitive cells [6] prior to the secondary binding of 
class F components, which then allows the expression of bio- 
logical activity. The biological activity results in the formation 
of pores of divalent ion size [10], thus activating neutrophils at 
sub-lytic levels which are responsible for neosynthesis and se- 
cretion of inflammatory mediators uch as leukotrien B4, inter- 
leukine-8, and histamine [14,17,23]. Inflammatory lesions can 
be observed after the intradermal injection of toxins to rabbits 
where PVL is responsible for acute necrosis [9,32]. 
Since S. intermedius is mostly involved in skin infection of 
small animals, the aim of this work was to characterise such a 
SHT-related toxin, and to establish its main characteristics. 
Staphylococcus intermedius (S. intermedius) is a coagulase- 
positive staphylococcus [13], whose ecology remains unclear. 
However, it is recognized as a veterinary pathogen which is 
essentially isolated from idiopathic superficial or deep recurrent 
skin infections of dogs and dog gingivitis [2,27]. In humans, the 
germ has been reported to be identified in infected varicose 
ulcers of elderly patients after dog bites in wounds and anterior 
nares [27,28]. Khambaty et al. [16] also reported an outbreak 
after food poisoning of butter blend. Infections and recurrent 
infections of dogs and food poisoning were the source of epi- 
demiological studies [2,15,16,27]. 
Phenotypic and immunological detections indicated that 
S. intermedius produces coagulase, enterotoxin A and C,/3- and 
6-hemolysins, protein A and proteolytic enzymes in common 
with Staphylococcus aureus (S. aureus) [1,3]. However, no mo- 
lecular characterisation f such compounds has been reported 
to date, except for the thermonuclease [4]. 
In the case of S. aureus, a closely related bacterium at the 
phenotypic level, Panton-Valentine leukocidin (PVL)-produc- 
ing strains were recently reported to be strongly associated with 
human furuncles [8,9,19] which can lead to recurrent skin pri- 
mary infections. The latter toxin (LukS-PV+LukF-PV) was 
recently cloned and sequenced [20]. It forms, with 7-haemolysin 
(HlgA, HlgB, HlgC) from S. aureus [7], a family of toxins acting 
by the synergy [12,33] of two secreted but non-associated pro- 
teins of class S (LukS-PV, HlgA, HlgC) and class F (LukF-PV, 
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2. Materials and methods 
2.1. Bacteria and animals 
Among the 53 strains of Staphylococcus intermedius tested in this 
study, 20 were provided by Prof. R.P. Allaker (Dental School of Lon- 
don), 12 by Dr. Wegener (National Veterinary Laboratory, Copen- 
hagen), 16 by N. E1 Solh (Institut Pasteur. Paris), and 5 by Y. Brun 
(Lyon). 44 of these strains were from canine origin, 8 from human 
origin, 1 from pigeon origin. Escherichia coli NM 522 [supE thi hsdR 
,J(lac-proAB) F" (proAB lacP ZM15)] was used as the host strain for the 
recombinant pUC19 plasmid [34]. 
2.2 Protein purification 
From a fresh culture of S. intermedius strain IBS 62 (or ATCC 51874) 
on sheep blood agar plate, one colony was grown for 6 h at 37°C with 
shaking in 3 ml of CCY-modified medium [11]. A 60/21 inoculum was 
then used to inoculate 20 ml of CCY-modified medium in each of the 
twelve 2-liter Erlenmeyer flasks containing a dialysis bag with a cut off 
of 6-8 kDa (Visking) filled with 120 ml of the same buffer. After 
overnight growth, the culture supernatant was centrifuged for 10 min 
at 15,000 x g at 4°C and then dialysed against 50 mM MES buffer, pH 
6.0. Each eluted fraction from chromatographies was tested for leu- 
kotoxicity as pairs, and also alone in combination with LukS-PV and 
LukF-PV. The first procedure was designed for a compound which was 
able to lyse the human glass-adherent leukocytes when combined with 
LukS-PV. The dialysed solution was then chromatographed through a
Mono S FPLC (Pharmacia-Uppsala, Sweden) with a linear gradient of 
0 to 500 mM LiC1 in MES 60 mM pH 6.0, and fractions containing 
proteins which were eluted between from 0 to 340 mM LiC1 were 
collected. This protein solution was adjusted to 0.8 M (NH4)2SO4 with 
50 mM phosphate buffer pH 7.0, 3 M (NH4)2SO 4 and chromatographed 
through an Alkyl Superose FPLC (Pharmacia-Uppsala, Sweden) with 
a linear gradient from 800 mM to 0 mM (NH4)2SO4. 
Another protein component, which when combined with LukF-PV 
induced leukotoxicity upon the same cells, was purified by a similar 
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procedure. Briefly, the culture supernatant was chromatographed 
through a MonoS FPLC in 50 mM Na-phosphate pH 7.0 with a linear 
gradient ranging from 100 mM to 600 mM NaCI. The protein fraction 
of interest was then adjusted to 1.5 M (NH4)2SO4 with 50 mM phos- 
phate buffer pH 7.0, 3 M (NH4)2SO 4 and chromatographed through an 
Alkyl Superose FPLC (Pharmacia-Uppsala, Sweden) in a 50 mM phos- 
phate buffer pH 7.0, with a linear gradient of (NH4)2SO4 ranging from 
1500 mM to 900 mM. 
Purified protein fractions were further analysed by SDS-PAGE [18] 
using the PHAST System (Pharmacia-Uppsalm Sweden). Characterisa- 
tion of the purified proteins was first carried out by N-terminal se- 
quencing (Laboratoire de G6n6tique Mol6culaire des Eucaryotes-Stras- 
bourg, France). 
2.3. Nucleic acids methods 
Total DNA from S. intermedius strains was prepared from a 15 ml 
overnight culture in 2 x TY medium as reported previously [25] for 
these strains except that protoplasts were obtained with a two-fold 
increased (20 U/ml) concentration f recombinant lysostaphin (Applied 
Microbiology Inc, New York, USA), and also (10 mg/ml) lysozyme 
(Appligene, Strasbourg-France). For the cloning of luk-L partial DNA 
libraries were constructed by selecting and ligating Accl-restricted 
DNA fragments ranging from 4.2 to 6.0 kb and DraI-restricted DNA 
fragments ranging from 1.7 to 2.3 kb, into the pUC19 plasmid lin- 
earised by Accl or Smal, respectively. After transformation f E. coli 
NM522, recombinant clones were screened as described previously [25] 
using a 5'-labelled egenerate oligonucleotide probe. This 33-mer ol- 
igonucleotide (5'-GAAGAAATCFFGGAGAAGGAGCA/C/TCAAA- 
TC/TATC/TAAA-Y) was deduced from the underlined sequence 
(ANTIEEIGEGAQIIK) of the N-terminal sequence of purified LukS- 
I, taking into account he codon usage for exoproteins from S. aureus. 
Nucleotide sequences were determined by the dideoxy chain termina- 
tion method [22] using T7 DNA polymerase [29] on double stranded 
DNA. The primers used initially were the universal primer and the 
cloning oligonucleotide and then those deduced from previous equenc- 
ing steps. Total RNA from S. intermedius train ATCC 51874 was 
prepared as described earlier [25]. DNA DNA [24] and RNA DNA 
[30] hybridizations were performed with a 1985 bp nick-translated 
DraI-DraI DNA fragment covering both lukS-I and lukF-I in 6 x 
SSPE, 5 x Denhardt's solution, 0.5% x SDS at 60°C for 16 h. Filters 
were then washed twice in 1 × SSPE, 0.5% x SDS at 50°C for 15 min. 
Sequence analysis was carried out using DNAStar software (DNAStar 
Ltd, London, UK). 
2.4. Leukocytolytic and haemolytic activity of SHT toxins 
The method used for the evaluation of Luk-I and the heterologous 
SHT toxins combined with LukS-I or LukF-I was as described previ- 
ously by Finck-Barbanqon et al. [11], and was performed with human 
and canine glass-adherent leukocytes. However, since it has been re- 
ported [6] that LakS-PV binds with K d = 6 nM to the membranes of
target cells prior to the interaction with LukF-PV, limiting amounts of 
class S components (not exceeding 1nM) were tested in the presence 
of an excess of class F components (50 ng or 1.55 pmol/20gtl) in 9.55%,, 
PBS-Dulbecco without Ca 2+- or Mg2+-0.5% gelatin. 
Haemolytic activity of the combination of LukS-1 and LukF-I with 
other SHT components was determined as reported previously [20] on 
human, rabbit, and dog erythrocytes, in the presence of an excess of 125 
ng of LukF-I or another class F component, per assay. 
2.5. Activity of SHT toxins in a rabbit skin model 
Shaved New Zealand rabbits (10 weeks old) were injected intrader- 
mally with 50/,tl of apyrogenic physiological medium containing equal 
amounts (3, 30, 100, 300, 1000, 3000, 10000 ng) of one class S- and one 
class F-related component. Assays were performed in duplicate. Mac- 
roscopic observations of the lesions were recorded after 0 h, 4 h, 24 h, 
48 h and lesions were biopsied under general anaesthesia induced by 
intramuscular injection of 250 ¢tl of reconstituted Zoletil-100 (Reading 
Laboratories, Carros-France). Skin biopsies were fixed in Bouin solu- 
tion, paraffin-embedded, cutin 4 mm-thick sections, then stained with 
hematoxylin-eosin-safran-astra blue. The tissue sections were examined 
in a 'blind' fashion. 
3. Results 
3.1. Characterisation of  a new SHT toxin 
A series of ten independent S. intermedius strains was grown 
overnight as described previously for the product ion of PVL 
and ),-hemolysin. The culture supernatants were then assayed 
for their leukotoxicity on human glass-adherent blood cells, by 
immunodiffusion and immunoblott ing using polyclonal anti- 
LukS-PV or ant i -LukF-PV affinity-purified antibodies. Culture 
supernatants appeared to be leukotoxic for human cells up to 
a 1/2000 fold dilution. The morphological changes of the super- 
natant-treated leukocytes were the same as those observed pre- 
viously by phase contrast microscopy of PVL-treated cells 
[11,12]. Immunodiffusion and immunoblots revealed the pres- 
ence of LukF-PV cross-reacting material (Fig. 1) with an appar- 
ent molecular mass of 3 ! kDa, but no protein was detected with 
LukS-PV polyclonal affinity-purified antibodies. 
The attempting to purify the leukocytolytic ompound pro- 
duced by S. intermedius ATCC 51874 by the previous purifica- 
tion protocol for PVL and ?,-hemolysin from S. aureus ATCC 
49775 allowed the purification of a class F-related protein 
which was first recovered through the MonoS FPLC, and fur- 
ther eluted at 150 mM (NH4)2SO 4 from the Alkyl-Superose 
FPLC. A class S-related protein was similarly obtained which 
was eluted at 350 mM NaC1 on MonoS FPLC and 1050 mM 
(NH4)2SO4 on Alkyl Superose FPLC. The yield of 2 mg of the 
purified class S-related and class F-related protein by liter of 
crude culture supernatant may reflect the yield of production, 
as well as the efficiency of purification. The latter was greatly 
improved for the purification of the class F-related component 
using 50 mM MES pH 6.0 buffer and LiC1 for the cation 
exchange chromatography. Protein fractions of interest were 
dialysed against 9.55%o PBS-Dulbecco without Ca 2÷ or Mg 2+ 
and stored frozen at -80°C to 1 A280 unit. SDS-PAGE of the 
purified proteins howed apparent molecular masses of 32 kDa 
and 35 kDa for the class S- and the class F-related protein (Fig. 
1), respectively. 
Table 1 
Leukotoxic specific activities on human PMN cells of each possible combination of LukS-I and LukF-I with SHT components 
Specific activity (U/mg) a±b when paired with: 
LukF-I b HlgB LukF-PV LukS-I HlgA HlgC LukS-PV 
LukS-I 9.7 × 107 9.7 x 105 2.9 x 105 < 104 < 104 < 104 < 104 
(+5x 10 6 ) (+5x 10 4 ) (+10 4) 
LukF-I < 10 4 < 10 4 < 10 4 9.7 × 10 7 1.2 x 10 6 3.5 x 10 ~ < 10 4 
(+ 5 x 10 ~') (+ 10 5) (_+ 10 4) 
"Values indicate the means of quadruplicate assays (+standard deviation). One unit is defined as the limiting amount of the class S component in 
the presence of an excess of class F component contained in dilutions producing 100% of the morphological changes in 105 glass-adsorbed PMN 
cells. 
bEach combination was tested in the presence of an excess of the class F component (50 ng). 
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Fig. 1. (A) SDS-PAGE analysis on PHAST system of the two components of the SHT produced by Staphylococcus intermedius. Lane 1:0.2/.tg of 
LukS-I. Lane 2:0.2 gtg of LukF-I. Lane 3:1/lg of molecular weight marker (Pharmacia, Uppsala, Sweden). (B) Immunoblot analysis of the immunoreactivity 
of LukS-I and LukF-I with anti-LukS-I (lanes 1 and 2) and anti-LukF-I (lanes 3 and 4) affinity-purified rabbit antibodies. Lane 1:0.5/.tg of purified 
LukS-I. Lane 2: culture supernatant of ATCC 51874. Lane 3:0.5 ,ug of purified LukF-1. Lane 4: culture supernatant of ATCC 51874. 
3.2. Cloning and sequencing of the SHT-encoding locus from 
S. intermedius 
The determination of the N-terminal extremities of the class 
S-related protein (ANTIEEIGEGAQIIK) and the class F-re- 
lated protein (ANQITPVSEKKVDDKIT) confirmed their ho- 
mology with previously sequenced proteins [7,20,25], which 
were called LukS-I and LukF-I, respectively. A degenerate 
oligonucleotide probe deduced from the N-terminal sequence 
of the class S-related protein was first tested for hybridisation 
with endonuclease-restricted total DNA of S. intermedius 
ATCC 51874 (data not shown). Four (BamHl, EcoR1, EcoRV, 
PvuII) out of the nine enzymes (AccI, ClaI, DraI, PstI, PvuII) 
tested gave hybridising DNA fragments longer than 8.0 kb, 
whereas the detected Dral-Dral and AccI-AccI DNA frag- 
ments were relatively short (< 3.0 kb). Two partial DNA 
libraries were constructed in pUC19 and recombinant clones 
were screened using the degenerate oligonucleotide probe. 
From the two different selected inserts, the nucleotide se- 
quences demonstrated that the DraI-DraI DNA fragment cov- 
ers two open reading frames (ORFs) and that one extremity of 
the AccI-AccI DNA fragment ended within the second ORF. 
A long insert including the two ORFs and upstream sequences 
was then created (Fig. 2) in pUC19 by first linearising the 
plasmid obtained from the screening of the DraI library, at the 
AccI site and excluding the 1.0 kb DNA fragment. The lin- 
earised plasmid was ligated with the 5.5 kb AccI-AccI insert 
from the plasmid obtained from the screening of the AccI li- 
brary. After selecting the in frame orientation, the resulted 
plasmid (pGUCI) was used to transform E. eoli NM522. Crude 
extracts of recombinant bacteria possessed a leukotoxic activity 
on human glass-adherent leukocytes after to be 11500 fold di- 
luted. 
A 2662 bp long nucleotide sequence of the pGUCI insert was 
determined (Fig. 3). The first ORF extended from nucleotide 
742 to 1674 and encoded a 310 amino acid long protein having 
a molecular mass of 35,056 Da. This ORF harboured 70.2%, 
71%, 70.1%, 67.8% identity with other class S proteins hlgA, 
hlgC, lukS-P V, and luk-M, respectively. Predicted transcription 
signals were found 19 and 32 nucleotides upstream to the ATG 
initiation codon of lukS-I and were designated as -35 and -10 
consensus equences. A putative ribosome binding site (rbs) 
was also found 8 bases upstream to the ATG. This rbs sequence 
is often encountered for staphylococcal genes. 
The second ORF was located one T downstream the stop 
codon of lukS-I, and extended from nucleotide 1676 to 2656, 
as was observed for the other co-transcribed genes encoding 
staphylococcal leukotoxins [7,20,25]. This ORF encodes a 326 
amino acid-long protein which has a molecular mass of 36,600 
Da. The corresponding nucleotide sequence had 76.1% and 
72.3% identity with ORFs with other class F components, hlgB 
and lukF-PV, respectively, whereas it has only 30% identity 
with ORFs encoding class S-related proteins. This gene was 
named lukF-l. No ORF was observed in the 740 bp preceeding 
lakS-l. Therefore, this locus is organised like luk-PV encoding 
PVL, rather than hlg encoding 7/-hemolysin and comprising 
three genes. No further ORF was found in the latter part of 
sequence. This nucleotide sequence was deposited in the 
EMBL/Genbank Database Library with the number X79188. 
3.3. Co-transcription of lukS-I and lukF-I 
Northern blot analysis (Fig. 4) of the hybridization of a 
nick-translated 1985 bp DraI-Dral DNA fragment covering 
both ORFs with total RNA from a culture (early stationary 
phase growth) of S. intermedius train ATCC 51874 showed 
that lukS-I and lukF-I are co-transcribed asa single 1950 base- 
long mRNA. Specific mRNA corresponding to as little as 
4 x 105 CFU (Fig. 4, lane 4) was detectable in this experiment. 
3.4. Peptide sequences and comparison 
From the peptide sequence deduced from lukS-L the deter- 
mined N-terminal peptide sequence was found 29 amino acids 
after the first residue. These 29 residues correspond to the 
signal peptide cleaved uring the secretion of the mature pro- 
tein and show a usual structure when compared with other 
staphylococcal signal peptides. Therefore, the mature protein 
LukS-I is 281 residues long with a molecular mass of 32,056 Da 
for a calculated e = 38,120 + 5% M -~'cm -~ and a calculated 
pI = 9.34 which were very close to those of other class S pro- 
teins. It contains 37 basic, 30 acidic, 90 hydrophobic and 85 
polar residues. 
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1 CCTC~ACTTG AATATTTATA TTGTTCACAC GTGCAAGTGG TACTACAGTT TCAAGCGTAC ~TATGG A ~ T A A  80 
81 ATGGCA~CCaA C A ~  CTCAAACCAC TTCACAAGGT ~ ~ TTTTCIX3ATA ATGGCGCCGT 160 
161 ATCAGACTTC ACCGTATGCT C C ~  ATGTCTTACA AAATAAATCK2 'FI'I'FI'ACCAT ~CCTCC CTTTAGAAAC 240 
241 CTTATCACTA ATAACAT?AA 'FI'I'FFI'ICAT GGCACATTTG A~CCAT AATATCCGGC G'i'ITI'ATAAA TGAATGTTTA 320 
321 T'ITAAAATAC TATTCC42TAA TAAAAAACAC AAAATAATCA ACAAAAGAAT TAACATATCA AAAACTTGAC TGTTTAATAC 400 
401 GAAAA TTC AAAGTTAATA AATAGTTAAT AATACAAATT TTAATCCACG CTAAATAAAA C~CTTA "ITI'I'AATATT 480 
481 ACTCCATTTA C A ~  TTCAACTACT CTATCCATCT qL~'FFI~X2A TTATCaATGAT A A T A ~  TCTAGATATA 560 
561 CCTTTCAAAA TCTI~'I'FI'I'I' ATTGTTGAAC ATGGATTTAT GTCaAAAAAAT GAACAAAGAA TATTCTATTA TGAAATAGTT 640 
641 AGGCTAACTC CTC'i'i'I-I'AAT AAATAGTTAA TTTTAAATTC ~ T A  TATTATGATG AAATTC//ATT AAAAGTATA~ 720 
-35 
721 ~ AATGGTAAAA AATAAATTAT T A l C  ACTATCTATA AGTITAATTC TTCCACTTAT 800 
1 -10 rbs M V K N K L L A A T L S I S L T L P L ~ 20 
801 TACCCCATAC AGTGAAGAAG CC3tKAGCI~aC AAACACTATA GAAGAAATCG GCGAAGGAGC ACAAATTATT AAAAGAACTG 880 
21 T P Y S E E A K A A N T I E E I G E G A Q I I K R T E 47 
881 AGGATGTAAG CAGCAGAAAA TGGGGCGT?A CTCAAAACAT TC.AGqTIC~C TTTGTTAAAG ACCCTAAATA CAACAAAGAT 960 
48 D V S S R K W G V T Q N I Q F D F V K D P K Y N K D 73 
961 GCATTAATTA TTAAAATGC.A ~ A T C  AAATCTAGAA CAA~-I-I'FI'AC I~-=AT~AAA GGGAAAGGAT ATGAATCAAC 1040 
74 A L I I K M Q G F I K S R T S F T D V K G K G Y E S T 100 
L041 A ~ T C  C T T T ~  TTCAATATAA TATTGCTCTA AAAACAAATG ATCCTAATGT OI'I'~'I'?AATT AATTATCTCC 1120 
i01 K R I L W P F Q Y N I A L K T N D P N V F L I N Y L p 127 
[121 CTAAAAATAA AATTGAATCA ATAGATGTCaA GCC/aAACATT AGGTTACAAT ~ A  A ~ G  TGCACCATTA 1200 
128 K N K I E S I D V S Q T L G Y N V G G N F Q S A P L 153 
[201 ~ A  AAGGCCaAATT TAATTATTCA AAC~KAAATTA GCTATACTCA AAAGAATTAT A T T ~ G  TCGCACAACA 1280 
154 L G G K G E F N Y S K K I S Y T Q K N Y I S E V A Q Q 180 
[281 AAATTCAAAA AATATCAGAT ~ i~CAAATTCA TTTAATACAG AAAATGGACA AGTATCAGCA TATGACAGAC 1360 
181 N S K N I R W E V K A N S F N T E N G Q V S A Y D R H 207 
[361 ACTTATTIX2~ AAGAAGTCCT A ~  ATGCAAGAGA t. ' l ' l 'FfTl~'I~ CCAAA'I~,ATG AGTTACCIL-~ TTTAATIX?AA 1440 
208 L F V R S P I G P N A R D F F V P N D E L P P L I Q 233 
[441 AGTGGTqTTA ATCCATCGTT TATTGCAACT GTATCTCATG AAAAAGATAA ~ T A C A  AGTGAATT~G AAATTGCTTA 1520 
234 S G F N P S F I A T V S H E K D K G D T S E F E I A Y 260 
L521 TGGTAGAAAT CTAF=ACATTA CGTATGCAAC ~ AGAACTGGCA T A ~  AAGACGTCAT AATGCTTTAA 1600 
261 G R N L D I T Y A T F F P R T G I F A E R R H N A L M 287 
1601 TGAATCC~ T C ~ C T  AAATATGAAG TC~CTGGAA AACACACGAA ATTAAAGTAA AGGGG~TAA TTAATATGAA 1680 
288 N R N L V T K Y E V N W K T H E I K V K G H N stopM K 2 
[681 AATAAGCAAA GTTATCAA~ CTGCTA~ AACATCCGTG GCATTGATGT TATTTTC~AA TCY2TGTCrAT ~ A A T C  1760 
3 I S K V I K A A T A q' S V A L M L F S N P V Y A A N Q 29 
[761 AAATTACACC T G T A ~  AAAAAGGTAG ACGATAAAAT CACTTTATAT AAGACTACCG CTACTGCAGA TIX2AC, ATAAC 1840 
30 I T P V S E K K V D D K I T L Y K T T A T A D S D N 55 
L841 TTAAATATTT CTCAACTCTT AA~;i-i'i-i~AT TITATTAAGG ATAAGAGCTA TGATAAGGAT ACCTTAGTAC TTAAAGCTGC 1920 
56 L N I S Q L L T F N F I K D K S Y D K D T L V L K A A 82 
i921 i~GGTAATA~ AACTCAGGTT ATAAAAGCCC TAACCCTAAC GACTATATCT ATTCAAG"FIT TTATTGC43GG GCTAAGTATA 2000 
83 G N I N S G Y K S P N P N D Y I Y S S F I W G A K Y N 109 
2001 ATGTGTC~T CAGTGCAGAA TCAAAAGGTG CT~AACGT AG~TTAT GCACCA~ ATCAAAATGA AGAGTTTCAA 2080 
110 V S I S A E S K G A V N V V D Y A P K N Q N E E F Q 135 
-)081 GTTCAAAACA CTCTAGGCTA Cq~.'i'i'i'IGGA GGAGACATTA G T A ~  A ~  GOCC.~a'~'L'I'IA ACGGCTCAGA 2160 
136 V Q N T L G Y S F G G D I S I S K G L S G G L N G S E 162 
-)161 AT~-ATTITCA GAAACAATAA ACTATAAACA GGAAAGTTAT AGAACAACTA TCGATAAACA CACAGATAAT AAAACTATTG 2240 
163 S F S E T I N Y K Q E S Y R T T I D K H T D N K T I G 189 
2241 ~ TGAAGCACAT AAAATCATGA A ~  ~ T A T  ~ G A T A  GCTTCCATGA CCTATATGGA 2320 
190 W G V E A H K I M N A G W G P Y G R D S F H D L Y G 215 
2321 AATGAA~ 'i'l'i'i'AGGtI~ TAGACAAAGT AAATTAAACG CTGGACAAAA CTTCTTACCT A C C ~  TGCCACTTTT 2400 
216 N E L F L G G R Q S K L N A G Q N F L P T R Q M P L L 242 
-)401 AGCAAGAGGT AACTTTAATC ~' l ' FF l ' l '  AAGTGTATTA TCACATAAAC C A A A ~  TAAAACATCA AAAATTAAAG 2480 
243 A R G N F N P E F L S V L S H K P N G A K T S K I K V 269 
~481 TCACGTATCA AAGAGAAATG GATGAGTATA CAAATTATI~G GAATGGCTTT CATTGGATGG GTACAAACTA TAAAAATCAA 2560 
270 T Y Q R E M D E Y T N Y W N G F H W M G T N Y K N Q 295 
1561 AACAATGCCA CATTTACATC A'i"i"I'I~%TGAA ATTGATTGGG ATCAGCATAC AGTAAAACTA ATCAAAACAC A ~ T G A  2640 
296 N N A T F T S F Y E I D W D Q H T V K L I K T H S D E 322 
-)641 AAAAAACCCA TCATAATTTA AA 2662 
323 K N P S stop 326 
Fig. 2. Schematic reconstruction of luk-1 from the two selected AccI-AccI and DraI-Dral inserts. 
From lukF-l, the previous determined N-terminal peptide 
sequence was found 26 amino acids after the first residue. The 
26 amino acids correspond to the signal peptide which contains 
basic residues at the N-terminal extremity, followed by hydro- 
phobic amino acids, generally encountered in staphylococcal 
secreted proteins. The secreted LukF-I would be 300 amino 
acids long with a molecular mass of 33,862 Da for a calculated 
= 57,180 + 5% M t.cm-~, and a calculated pI = 7.54 which 
differs from those of other class F proteins, being more alka- 
line. The mature LukF-I would contain 32 basic and 32 acidic, 
82 hydrophobic and 109 polar amino acids. 
When compared with homofunctional components of other 
SHT, LukS-I harboured identity in the range of 65% to 67% 
with LukS-PV, HlgA and HlgC, and Luk-M whereas LukF-I 
has 72% and 73% identity with LukF-PV and HIgB, respec- 
tively. Amino acid differences were distributed throughout the 
sequences. 
3.5. Leukotoxic and haemolytic activities of LukS.l  and LukF_i 
Since each SHT component of class S and class F compo- 
nents exhibited synergistic activity [12,33], and since class S 
components bind membranes prior the interaction of the class 
F components [6], LukS-I and LukF-I were tested in combina- 
tion (Table 1) with staphylococcal class F and class S compo- 
nents, respectively. The couple LukS-! + LukF-I has a very high 
biological activity of 9.7 × 107 U/mg on human glass-adherent 
blood cells which is comparable [20] with that of PVL (LukS- 
PV+LukF-PV). Despite being 100-fold less effective than 
LukS-I + LukF-I, LukS-I is still able to induce significant leu- 
kotoxicity when combined with class F components produced 
by S. aureus such as HlgB and LukF-PV. Only the combination 
of LukS-PV + LukF-I had no significant effect nor did compo- 
nents belonging to one class. However, LukF-I was able to 
induce leukotoxicity in combination with HlgA and HlgC, the 
two S-related components from y-haemolysin. LukS-I + LukF-I 
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Fig. 3. Nucleotide sequence of the cotranscribed lukS-I and lukF-I 
constituting the luk-I operon. Predicted transcription consensus e- 
quences (-35 and -10), and ribosome binding site (rbs) are underlined 
upstream lukS-I which extends from nucleotide 742 to 1674. The other 
ORF encoding lukF-I extended from position 1676 to 2656. Peptide 
sequences ofLukS-I (310 residsues) and of LukF-I are indicated under 
nucleotide sequences. Probable signal peptides are also underlined. 
also showed a high toxicity (3.8 x 107 U/mg of LukS-I) on 
canine glass-adherent blood cells, whereas other combinations 
appeared ineffective on these cells. 
The haemolytic activity of LukS-I+LukF-I  was quite low 
(5 × 103 U/mg) when tested on rabbit erythrocytes, if compared 
to the couples HIgA + HlgB and LukS-I + HlgB (5 x 107 U/mg), 
but the couple HIgA + LukF-I had no more activity. The other 
combination of SHT components with LukS-I or LukF-I did 
not exhibit significant haemolytic activity. The above couples 
also did not harbour any significant haemolytic activity 
(< 5 × 10 2 U/mg). 
3.6. Dermonecrotic activity of  LukS-I  and LukF-I  
Intradermal injections of LukS-I + LukF-I in rabbit skin were 
performed as for PVL in a previous work [9]. For injections of 
the physiological solution or the 10,000 ng dose of proteins 
alone, there was a small erythema which disappeared within 48 
h. At the dose of 3 ng of both components, a slight erythema 
was observed 24 h after injection which persisted until 48 h. At 
the 30 ng dose, large and infiltrated erythema was obtained in 
all cases at 24 h and 48 h after injection. At 100 ng doses or 
higher, there was eshar formation 24 h after injection with 
dose-dependent necrosis at 48 h. Lesions healed within 10 days 
except for doses of 1000 ng and greater. Histological changes 
were as observed after injection of PVL [9] and were chro- 
nologically: vasodilatation, diapedesis, perivascular infiltra- 
tion, leukocytoclasis, vascular and tissue necrosis arround the 
site of injection. 
3.7. D&tribution of  genes encoding lukS-I and lukF-I & 
Staphylococcus intermedius 
All of the 51 total DNAs isolated from strains of Staphylo- 
coccus intermedius of different origin hybridised with the DraI- 
DraI lukS-I/lukF-I probe. As shown in Fig. 5, two different 
length of PstI-Pstl DNA fragments may carry the genes encod- 
ing LukS-I and LukF-I, indicating two possible genetic ar- 
rangements in the vicinity of the corresponding ORFs. How- 
ever, a majority (42 strains) of total DNAs harboured a genetic 
location of luk-I similar to that of strain ATCC 51874. No 
139 
typical association was evident among the S. intermedius strains 
for either location. Culture supernatants ofall strains appeared 
strongly leukotoxic and had biological activity even when 1/ 
3000 fold diluted in PBS-gelatin. Immunodiffusion assays gave 
similar results as strain ATCC 51874. 
4. Discussion 
Although S. intermedius can be considered as a close bacteria 
with many phenotypes in common with S. aureus, it seems a 
more adapted pathogen to small animals. The two species may 
have diverged recently in the evolution and may have conserved 
the same process of pathogenicity against their respective hosts. 
Effectively, several virulence factors appeared to be encoun- 
tered in the two bacteria. Here is the molecular characterisation 
of a leucotoxin from S. interrnedius which is related with a 
recently described family of toxins produced by S. aureus 
[5,7,20,25], and different class S components may be inter- 
changeable in order to give biological activity when combined 
with class F components. 
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Fig. 4. Northern blot analysis evidenced the cotranscription f lukS-I 
and lukF-l. Lanes 1 to 5: Total RNA from 4x l0 s, 4x 10 7, 4x 10 6, 
4 x 105, 4 x 10 4 CFU,  respectively, was hybridised to a nick-translated 
DraI-Dral DNA fragment covering both lukS-I and lukF-l. 
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Fig. 5. Southern analysis howed two genetic arrangements for luk-I in 
the genome from Staphylococcus intermedius. Lane 1: 5"-labelled DNA 
fragment from total DNA of bacteriophage 2, hydrolysed with BstEII. 
Lanes 2 to 16: DNA-DNA hybridisation of total DNAs hydrolysed 
with PstI from 19 of the 51 Staphylococcus intermedius strains with the 
DraI-Dral lukS-IllukF-I probe. 
As earlier mentioned, some consistent differences exist be- 
tween Panton-Valentine leucocidin and gamma-haemolysin at 
the molecular level, but also concerning their genetic organisa- 
tion, their gene distribution among clinical strains, their cell 
specificity, and their possible association to a clinical syndrome. 
The sequenced toxin produced by S. intermedius hares everal 
aspects of SHT toxins since it is encoded by two cotranscribed 
genes eparated by only one base. Furthermore, the gene prod- 
ucts which are secreted separately acquired biological activity 
at surface of target cells only when combined each other or with 
heterologous components from other staphylococcal SHT tox- 
ins. The new member of the toxin family which has more or less 
common epitopes with other toxins, has common characters 
with y-haemolysin because it is largely spread in independant 
strains of S. intermedius, and also with PVL since it is encoded 
by only two consecutive ORFs. LukS-I + LukF-I is highly leu- 
cotoxic on human and also on canine PMNs, but despite a 
slight activity on rabbit erythrocytes, it is not significantly he- 
molytic on cells from various mammalians. The latter proper- 
ties may reflect differing specificity on target cells surface which 
is currently being investigated. Moreover, the S. intermedius 
leucotoxin has a sequence structure which is as divergent from 
y-haemolysin as PVL, but which may have common tridimen- 
sional domains designing the functional basis of such com- 
pounds. 
In conclusion, the new toxin which is the first characterised 
one from S. intermedius strengthens the notion of a toxin family 
produced by some of Staphylococcus species. Whereas one of 
the SHT toxins seemed to have a role in the outcoming of a 
clinical syndrome [8,9], the conserved properties of these toxins 
in several pathogenic bacteria suggest that SHT toxins are 
important virulence factors whose precise role remains to be 
determined uring infections. 
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